Improved metabolic profile after switch to darunavir/ritonavir in HIV positive patients previously on protease inhibitor therapy

Antihypertensive and metabolic effects of telmisartan in hypertensive HIV-positive patients

(2011) Jacopo Vecchiet et al.   ANTIVIRAL THERAPY

Cystatin C, Adipokines and Cardiovascular Risk in HIV Infected Patients

(2010) Katia Falasca et al.   CURRENT HIV RESEARCH

Effect of simplification from protease inhibitors to boosted atazanavir-based regimens in real-life conditions

(2010) R Rubio et al.   HIV MEDICINE

Markers of Inflammation, Coagulation, and Renal Function Are Elevated in Adults with HIV Infection

(2010) Jacqueline Neuhaus et al.   JOURNAL OF INFECTIOUS DISEASES

Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48

(2009) Roberto Ortiz et al.   AIDS

Effects of First-Line Use of Nucleoside Analogues, Efavirenz, and Ritonavir-Boosted Protease Inhibitors on Lipid Levels

(2009) Andrew Hill et al.   HIV CLINICAL TRIALS

Cystatin C—A marker of peripheral atherosclerotic disease?

(2008) J. Arpegård et al.   ATHEROSCLEROSIS

Efficacy of Once-Daily Darunavir/Ritonavir 800/100 mg in HIV-Infected, Treatment-Experienced Patients With No Baseline Resistance-Associated Mutations to Darunavir

(2008) Sandra M J De Meyer et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Follow-up of a multi-drug resistant HIV-1 infected patient successfully treated with darunavir and etravirine

(2008) Anne Margrethe Audelin et al.   JOURNAL OF MEDICAL VIROLOGY

Microalbuminuria associated with indicators of inflammatory activity in an HIV-positive population

(2008) M. Baekken et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION